Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of [14C]-Afatinib in Healthy Volunteers
NCT02171689Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Primary completion
- Aug 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: [14C]-radioactivity in plasma and whole blood up to 96 hours, [14C]-radioactivity in urine and faeces up to 120 hours and 3 more. Started Jul 2006; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02171689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171689.